These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20002090)

  • 1. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study.
    Beghetti M; Haworth SG; Bonnet D; Barst RJ; Acar P; Fraisse A; Ivy DD; Jais X; Schulze-Neick I; Galiè N; Morganti A; Dingemanse J; Kusic-Pajic A; Berger RM
    Br J Clin Pharmacol; 2009 Dec; 68(6):948-55. PubMed ID: 20002090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.
    Berger RMF; Gehin M; Beghetti M; Ivy D; Kusic-Pajic A; Cornelisse P; Grill S; Bonnet D;
    Br J Clin Pharmacol; 2017 Aug; 83(8):1734-1744. PubMed ID: 28213957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan: in pediatric patients with pulmonary arterial hypertension.
    Carter NJ; Keating GM
    Paediatr Drugs; 2010; 12(1):63-73. PubMed ID: 20034342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
    Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
    Barst RJ; Ivy D; Dingemanse J; Widlitz A; Schmitt K; Doran A; Bingaman D; Nguyen N; Gaitonde M; van Giersbergen PL
    Clin Pharmacol Ther; 2003 Apr; 73(4):372-82. PubMed ID: 12709727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
    Dingemanse J; van Giersbergen PL
    Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
    Berger RM; Haworth SG; Bonnet D; Dulac Y; Fraisse A; Galiè N; Ivy DD; Jaïs X; Miera O; Rosenzweig EB; Efficace M; Kusic-Pajic A; Beghetti M
    Int J Cardiol; 2016 Jan; 202():52-8. PubMed ID: 26386921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.
    Douwes JM; Roofthooft MT; Van Loon RL; Ploegstra MJ; Bartelds B; Hillege HL; Berger RM
    Heart; 2014 Feb; 100(3):224-30. PubMed ID: 24390161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension: A multiple ascending-dose study.
    Small D; Ferguson-Sells L; Dahdah N; Bonnet D; Landry J; Li B
    Br J Clin Pharmacol; 2019 Oct; 85(10):2302-2309. PubMed ID: 31222765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension.
    Savale L; Magnier R; Le Pavec J; Jaïs X; Montani D; O'Callaghan DS; Humbert M; Dingemanse J; Simonneau G; Sitbon O
    Eur Respir J; 2013 Jan; 41(1):96-103. PubMed ID: 22653773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term bosentan in children with pulmonary arterial hypertension.
    Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
    J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
    Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
    Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for the treatment of pulmonary arterial hypertension.
    Kenyon KW; Nappi JM
    Ann Pharmacother; 2003; 37(7-8):1055-62. PubMed ID: 12841819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
    Fine N; Dias B; Shoemaker G; Mehta S
    Can J Cardiol; 2009 Mar; 25(3):e63-8. PubMed ID: 19279988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
    Ivy DD; Rosenzweig EB; Lemarié JC; Brand M; Rosenberg D; Barst RJ
    Am J Cardiol; 2010 Nov; 106(9):1332-8. PubMed ID: 21029834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil.
    Burgess G; Hoogkamer H; Collings L; Dingemanse J
    Eur J Clin Pharmacol; 2008 Jan; 64(1):43-50. PubMed ID: 18040672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
    Ibrahim R; Granton JT; Mehta S
    Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension].
    Xu ZM; Zhu LM; Cai XM; Ji G; Liu JF; Su ZK
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2106-9. PubMed ID: 20058613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP; Humbert M; Rubin L; Black CM
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.